Galactosemia Foundation Urges FDA to Incorporate Voice of the Patient in Review of Potential First Treatment for Children with Life-Altering Rare Disease

Govorestat (AT-007) demonstrates consistent and sustained clinical benefit in children with galactosemia across symptoms of greatest concern to patients and caregivers ALBANY, N.Y., April 26, 2023 /PRNewswire/ — The Galactosemia Foundation, a non-profit charitable organization that…